Kelly Stefano Cole1, Judith M Martin2, William T Horne2, Chyongchiou J Lin3, Mary Patricia Nowalk3, John F Alcorn2, Richard K Zimmerman4. 1. Department of Immunology and Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: zimmer@pitt.edu.
Abstract
BACKGROUND: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV). To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV. METHODS: Children 3-17years of age receiving quadrivalent influenza vaccine were enrolled. Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10days) following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log2 transformed and compared between the two vaccine groups. RESULTS: Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in both groups. CONCLUSIONS: Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients. These results help to elucidate the immune response to influenza vaccines and may be related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.
BACKGROUND: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV). To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV. METHODS:Children 3-17years of age receiving quadrivalent influenza vaccine were enrolled. Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10days) following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log2 transformed and compared between the two vaccine groups. RESULTS: Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in both groups. CONCLUSIONS: Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients. These results help to elucidate the immune response to influenza vaccines and may be related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.
Authors: Jin Hyang Kim; Margarita Mishina; Jessie R Chung; Kelly Stefano Cole; Mary Patricia Nowalk; Judith M Martin; Sarah Spencer; Brendan Flannery; Richard K Zimmerman; Suryaprakash Sambhara Journal: J Infect Dis Date: 2016-08-17 Impact factor: 5.226
Authors: John S Tsang; Pamela L Schwartzberg; Yuri Kotliarov; Angelique Biancotto; Zhi Xie; Ronald N Germain; Ena Wang; Matthew J Olnes; Manikandan Narayanan; Hana Golding; Susan Moir; Howard B Dickler; Shira Perl; Foo Cheung Journal: Cell Date: 2014-04-10 Impact factor: 41.582
Authors: Yan Tan; Pablo Tamayo; Helder Nakaya; Bali Pulendran; Jill P Mesirov; W Nicholas Haining Journal: Eur J Immunol Date: 2013-11-29 Impact factor: 5.532
Authors: Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran Journal: Nat Immunol Date: 2011-07-10 Impact factor: 25.606
Authors: Kristen L Hoek; Parimal Samir; Leigh M Howard; Xinnan Niu; Nripesh Prasad; Allison Galassie; Qi Liu; Tara M Allos; Kyle A Floyd; Yan Guo; Yu Shyr; Shawn E Levy; Sebastian Joyce; Kathryn M Edwards; Andrew J Link Journal: PLoS One Date: 2015-02-23 Impact factor: 3.240
Authors: Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman Journal: Clin Vaccine Immunol Date: 2016-10-04
Authors: David Furman; Vladimir Jojic; Brian Kidd; Shai Shen-Orr; Jordan Price; Justin Jarrell; Tiffany Tse; Huang Huang; Peder Lund; Holden T Maecker; Paul J Utz; Cornelia L Dekker; Daphne Koller; Mark M Davis Journal: Mol Syst Biol Date: 2013-04-16 Impact factor: 11.429
Authors: John F Alcorn; Raghunandan Avula; Anish B Chakka; William E Schwarzmann; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Marianna A Ortiz; William T Horne; Uma R Chandran; Jennifer P Nagg; Richard K Zimmerman; Kelly S Cole; Krissy K Moehling; Judith M Martin Journal: Hum Vaccin Immunother Date: 2020-04-16 Impact factor: 3.452
Authors: Katherine V Williams; Bo Zhai; John F Alcorn; Mary Patricia Nowalk; Min Z Levine; Sara S Kim; Brendan Flannery; Krissy Moehling Geffel; Amanda Jaber Merranko; Jennifer P Nagg; Mark Collins; Michael Susick; Karen S Clarke; Richard K Zimmerman; Judith M Martin Journal: Vaccine Date: 2021-12-21 Impact factor: 3.641
Authors: Judith M Martin; Raghunandan Avula; Mary Patricia Nowalk; Chyongchiou Jeng Lin; William T Horne; Uma R Chandran; Jennifer P Nagg; Richard K Zimmerman; Kelly S Cole; John F Alcorn Journal: Open Forum Infect Dis Date: 2018-10-24 Impact factor: 3.835